Quantcast
Last updated on April 24, 2014 at 5:30 EDT

Latest Selectins Stories

2013-08-19 08:28:31

SUSTAIN study to investigate the potential of a chronic SelG1 therapy to reduce or prevent the occurrence of sickle cell-related pain crises OKLAHOMA CITY, Aug. 19, 2013 /PRNewswire/ -- Selexys Pharmaceuticals Corporation, a privately held biopharmaceutical company that is developing therapies to treat inflammatory and thrombotic diseases, today announced that enrollment has been initiated in SUSTAIN, a Phase II, multicenter, randomized, placebo-controlled, double-blind, 12-month...

2013-04-12 16:06:55

A new technique based on atomic force microscopy was developed at the Institute of Food Research to help ℠read´ information encoded in the gut lining. The lining of our gut is an important barrier between the outside world and our bodies. Laid out, the gut lining would cover the area of a football pitch. It must let nutrients from our foods through, but prevent invasion by disease-causing bacteria, at the same time hosting the trillions of beneficial bacteria needed for proper...

2013-01-24 13:44:54

With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body's inflammatory response and how malignant breast cancer cells use the bloodstream to spread. (PLOS ONE, Jan. 23, 2013) Pro-inflammatory signaling molecules in blood called cytokines constitute a "switch" that induces the mechanism by which breast cancer cells "roll" and adhere to the blood vessel surface. The cancer cells eventually stick to the vessel and infiltrate it. The...

2012-12-11 21:38:00

A new study published in Biological Psychiatry suggests that autism is associated with reductions in the level of cellular adhesion molecules in the blood, where they play a role in immune function. Cell adhesion molecules are the glue that binds cells together in the body. Deficits in adhesion molecules would be expected to compromise processes at the interfaces between cells, influencing tissue integrity and cell-to-cell signaling. In the brain, deficits in adhesion molecules could...

2012-09-19 02:30:49

OKLAHOMA CITY, Sept. 19, 2012 /PRNewswire/ -- Selexys Pharmaceuticals, Corp., announced today that it has successfully completed a $23 million Series A equity financing, led by MPM Capital. Additionally, Selexys entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell...

2011-12-19 09:00:00

OKLAHOMA CITY, Dec. 19, 2011 /PRNewswire/ -- Selexys Pharmaceuticals announced today that it has completed a Phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin. The placebo-controlled, double-blind, ascending single dose and multiple dose study of SelG1 enrolled 27 healthy subjects. The study evaluated the safety and pharmacology of SelG1 to support its advancement into a Phase II clinical trial in...

2010-10-22 10:39:00

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Energid Technologies Corporation has been funded by the U.S. Department of Agriculture to develop a commercial robotic citrus harvesting system. In the 2009-ended season, 12 million tons of citrus were harvested in the United States, of which about 3.5% were removed through shaking. The rest, approximately 50 billion individual fruits, had to be picked by hand, often in adverse weather, often from ladders. This happens year after year. The...

2010-06-10 15:28:14

Several years ago, Dr. Arthur Beaudet, Baylor College of Medicine's chair of molecular and human genetics, was surprised to find that mice that lacked a protein called E-selectin ligand-1 were shorter than normal. He and his colleagues were hoping that the protein was involved in cell adherence, but instead their mice had a form of dwarfism. They turned the mice and their data over to Dr. Brendan Lee, a professor of molecular and human genetics at BCM, and an expert in the development of...

2009-06-25 14:33:16

It is now possible to engineer tiny containers the size of a virus to deliver drugs and other materials with almost 100 percent efficiency to targeted cells in the bloodstream.According to a new Cornell study, the technique could one day be used to deliver vaccines, drugs or genetic material to treat cancer and blood and immunological disorders. The research is published today (June 25, 2009) online at the Web site of the journal Gene Therapy."This study greatly extends the range of...

2008-12-12 10:19:20

In a new tactic in the fight against cancer, Cornell researcher Michael King has developed what he calls a lethal "lint brush" for the blood -- a tiny, implantable device that captures and kills cancer cells in the bloodstream before they spread through the body.The strategy, which takes advantage of the body's natural mechanism for fighting infection, could lead to new treatments for a variety of cancers, said King, who is an associate professor of biomedical engineering.In research...